The Europe Veterinary Vaccines Market should witness market growth of 5.3% CAGR during the forecast period (2023-2029).
The main reasons for the widespread acceptance of ruminants, especially cattle vaccinations, around the region are the rising outbreaks of cattle disease and the continuously growing livestock population. Animals are an essential source of food, protein, and other industrial goods like wool and leather. Equine influenza, foot & mouth disease, and rabies vaccinations are the three most frequently administered to animals. These vaccinations prevent the transmission of dangerous pathogens by imitating the body's naturally developed immunity.
The need for animal vaccines for the cattle population is rising due to growing concerns about food security and improved animal husbandry. In addition, livestock output has increased due to rising consumer demand for animal products. The demand for animal products is also rising due to a number of variables, including changes in food choices brought on through shifting lifestyles and population expansion, therefore such elements are contributing to the market's growth.
A zoonosis of growing clinical importance is the hantavirus illness. With more than 2800 cases reported, Germany's incidence peaked for the first time in 2012. These viruses can spread from small mammals to people. Clinically significant infections are brought on by two hantavirus species in Germany. Every two to three years, the Puumala virus, spread by bank voles, produces significant illness epidemics in Germany's southwest, west, and Bavarian forests. In addition, infections are brought on by the Dobrava-Belgrad virus, which striped field mice spread throughout the north and east of the nation. Thus, the demand is anticipated to rise in response to the rising prevalence of zoonotic diseases to prevent these illnesses from affecting the human population, supporting regional market expansion.
The Germany market dominated the Europe Veterinary Vaccines Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $755 million by 2029. The UK market is estimated to grow a CAGR of 4.4% during (2023-2029). Additionally, The France market would showcase a CAGR of 6.1% during (2023-2029).
Based on Route of Administration, the market is segmented into Injection Vaccines, Oral Vaccines and Intranasal/Spray Vaccines. Based on Type, the market is segmented into Livestock Vaccines, Porcine Vaccines, Companion Animal Vaccines, Poultry Vaccines, Aquaculture Vaccines and Others. Based on Technology, the market is segmented into Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines and Others. Based on Distribution Channel, the market is segmented into Veterinary Hospitals, Veterinary Clinics and Retail Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zoetis, Inc., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health, Inc., Virbac, Ceva Santé Animale, Neogen Corporation, Intas Pharmaceuticals Ltd. and Laboratoire LCV.
The main reasons for the widespread acceptance of ruminants, especially cattle vaccinations, around the region are the rising outbreaks of cattle disease and the continuously growing livestock population. Animals are an essential source of food, protein, and other industrial goods like wool and leather. Equine influenza, foot & mouth disease, and rabies vaccinations are the three most frequently administered to animals. These vaccinations prevent the transmission of dangerous pathogens by imitating the body's naturally developed immunity.
The need for animal vaccines for the cattle population is rising due to growing concerns about food security and improved animal husbandry. In addition, livestock output has increased due to rising consumer demand for animal products. The demand for animal products is also rising due to a number of variables, including changes in food choices brought on through shifting lifestyles and population expansion, therefore such elements are contributing to the market's growth.
A zoonosis of growing clinical importance is the hantavirus illness. With more than 2800 cases reported, Germany's incidence peaked for the first time in 2012. These viruses can spread from small mammals to people. Clinically significant infections are brought on by two hantavirus species in Germany. Every two to three years, the Puumala virus, spread by bank voles, produces significant illness epidemics in Germany's southwest, west, and Bavarian forests. In addition, infections are brought on by the Dobrava-Belgrad virus, which striped field mice spread throughout the north and east of the nation. Thus, the demand is anticipated to rise in response to the rising prevalence of zoonotic diseases to prevent these illnesses from affecting the human population, supporting regional market expansion.
The Germany market dominated the Europe Veterinary Vaccines Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $755 million by 2029. The UK market is estimated to grow a CAGR of 4.4% during (2023-2029). Additionally, The France market would showcase a CAGR of 6.1% during (2023-2029).
Based on Route of Administration, the market is segmented into Injection Vaccines, Oral Vaccines and Intranasal/Spray Vaccines. Based on Type, the market is segmented into Livestock Vaccines, Porcine Vaccines, Companion Animal Vaccines, Poultry Vaccines, Aquaculture Vaccines and Others. Based on Technology, the market is segmented into Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines and Others. Based on Distribution Channel, the market is segmented into Veterinary Hospitals, Veterinary Clinics and Retail Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zoetis, Inc., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health, Inc., Virbac, Ceva Santé Animale, Neogen Corporation, Intas Pharmaceuticals Ltd. and Laboratoire LCV.
Scope of the Study
By Route of Administration
- Injection Vaccines
- Oral Vaccines
- Intranasal/Spray Vaccines
By Type
- Livestock Vaccines
- Porcine Vaccines
- Companion Animal Vaccines
- Poultry Vaccines
- Aquaculture Vaccines
- Others
By Technology
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Others
By Distribution Channel
- Veterinary Hospitals
- Veterinary Clinics
- Retail Pharmacies
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Zoetis, Inc.
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Elanco Animal Health, Inc.
- Virbac
- Ceva Santé Animale
- Neogen Corporation
- Intas Pharmaceuticals Ltd.
- Laboratoire LCV
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe Veterinary Vaccines Market by Route of Administration
Chapter 5. Europe Veterinary Vaccines Market by Type
Chapter 6. Europe Veterinary Vaccines Market by Technology
Chapter 7. Europe Veterinary Vaccines Market by Distribution Channel
Chapter 8. Europe Veterinary Vaccines Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Zoetis, Inc.
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Elanco Animal Health, Inc.
- Virbac
- Ceva Santé Animale
- Neogen Corporation
- Intas Pharmaceuticals Ltd.
- Laboratoire LCV
Methodology
LOADING...
